Reviewing INmune Bio Inc. (INMB)’s and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)’s results

This is therefore a contrasting of the dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation in INmune Bio Inc. (NASDAQ:INMB) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
INmune Bio Inc. N/A 0.00 10.99M -0.98 0.00
EyePoint Pharmaceuticals Inc. 4.57M 51.32 86.13M -1.35 0.00

Table 1 highlights INmune Bio Inc. and EyePoint Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.


Table 2 shows INmune Bio Inc. and EyePoint Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
INmune Bio Inc. 0.00% 0% 0%
EyePoint Pharmaceuticals Inc. -1,884.68% -414.6% -142.9%


The Current Ratio and a Quick Ratio of INmune Bio Inc. are 5.5 and 5.5. Competitively, EyePoint Pharmaceuticals Inc. has 2.6 and 2.6 for Current and Quick Ratio. INmune Bio Inc.’s better ability to pay short and long-term obligations than EyePoint Pharmaceuticals Inc.

Institutional and Insider Ownership

Roughly 7.2% of INmune Bio Inc. shares are held by institutional investors while 62.3% of EyePoint Pharmaceuticals Inc. are owned by institutional investors. Insiders held roughly 16.3% of INmune Bio Inc.’s shares. Comparatively, insiders own roughly 0.5% of EyePoint Pharmaceuticals Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
INmune Bio Inc. -7.25% 0% 0% 0% 0% -5.51%
EyePoint Pharmaceuticals Inc. -2.21% 21% 28.64% 25% 150% 40.21%

For the past year INmune Bio Inc. had bearish trend while EyePoint Pharmaceuticals Inc. had bullish trend.


On 6 of the 9 factors INmune Bio Inc. beats EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.